EPS for Marlin Gold Mining Ltd (MLN) Expected At $-0.02; Seattle Genetics, Inc. (SGEN) Covered By 6 Bulls

August 10, 2017 - By Adrian Erickson

Analysts expect Marlin Gold Mining Ltd (CVE:MLN) to report $-0.02 EPS on September, 4.They anticipate $0.02 EPS change or 50.00% from last quarter’s $-0.04 EPS. The stock increased 5.38% or $0.05 on August 9, reaching $0.98. About 12,000 shares traded. Marlin Gold Mining Ltd (CVE:MLN) has 0.00% since August 10, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 15 analysts covering Seattle Genetics (NASDAQ:SGEN), 6 have Buy rating, 1 Sell and 8 Hold. Therefore 40% are positive. Seattle Genetics had 36 analyst reports since July 31, 2015 according to SRatingsIntel. The company was maintained on Tuesday, June 6 by Cowen & Co. The firm has “Hold” rating by Oppenheimer given on Monday, July 24. The stock has “Outperform” rating by Credit Suisse on Thursday, January 21. As per Wednesday, July 27, the company rating was maintained by Barclays Capital. The rating was maintained by Cantor Fitzgerald on Monday, June 19 with “Hold”. The company was maintained on Tuesday, December 6 by RBC Capital Markets. The firm earned “Hold” rating on Monday, June 19 by Cowen & Co. As per Monday, July 24, the company rating was maintained by Piper Jaffray. The rating was maintained by William Blair on Tuesday, August 25 with “Buy”. The firm has “Outperform” rating by RBC Capital Markets given on Friday, July 31. See Seattle Genetics, Inc. (NASDAQ:SGEN) latest ratings:

27/07/2017 Broker: Cowen & Co Rating: Hold New Target: $54.0000 Maintain
24/07/2017 Broker: Piper Jaffray Rating: Hold New Target: $48.0000 Maintain
24/07/2017 Broker: Oppenheimer Rating: Hold Maintain
26/06/2017 Broker: Cowen & Co Rating: Hold New Target: $54.0000 Maintain
26/06/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $43.0000 Maintain
26/06/2017 Broker: Oppenheimer Rating: Hold Maintain
20/06/2017 Broker: Leerink Swann Rating: Buy New Target: $66.0000
19/06/2017 Broker: Needham Rating: Buy New Target: $72.0000 Maintain
19/06/2017 Broker: Cowen & Co Rating: Hold Maintain
19/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $75.0000 Maintain

Marlin Gold Mining Ltd. is engaged in the exploration for, development of and production of gold in Mexico, silver in Arizona and acquiring royalty streaming agreements. The company has market cap of $168.38 million. The Firm operates through the production of gold and exploration of resources segment. It currently has negative earnings. The Company’s principal product is gold dore with the refined gold bullion sold in the London spot market by the subsidiary in Barbados.

Seattle Genetics, Inc. is a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The company has market cap of $6.97 billion. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. It currently has negative earnings. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate .

Investors sentiment increased to 1.2 in Q4 2016. Its up 0.20, from 1 in 2016Q3. It is positive, as 30 investors sold Seattle Genetics, Inc. shares while 73 reduced holdings. 60 funds opened positions while 64 raised stakes. 135.77 million shares or 1.02% less from 137.16 million shares in 2016Q3 were reported. Vident Invest Advisory Limited Liability owns 3,321 shares. 6,272 were reported by Twin Tree Limited Partnership. 12,900 are held by Gotham Asset Mngmt Ltd Com. Atria Investments Ltd Company invested 0.02% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Moreover, Neuberger Berman Lc has 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). Great West Life Assurance Co Can owns 41,340 shares. Quantbot Limited Partnership holds 0.01% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 1,049 shares. Brown Advisory owns 33,211 shares. Commerzbank Aktiengesellschaft Fi holds 0.04% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 52,945 shares. Employees Retirement Association Of Colorado invested 0.01% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Amp Capital Ltd accumulated 0.01% or 23,733 shares. 32,284 are owned by Hanseatic Mgmt. 2,500 are held by First Manhattan. Pointstate Lp holds 50,000 shares or 0.04% of its portfolio. Stevens Cap Mgmt L P, Pennsylvania-based fund reported 5,121 shares.